AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 211.43B +27.4% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.11 |
| Forward PE | 17.10 |
| Dividend | 2.36 (1.73%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,785,841 |
| Average Volume | 2,194,545 |
| Open | 13,800 |
| Previous Close | 13,740 |
| Day's Range | 13,554 - 13,892 |
| 52-Week Range | 9,932 - 15,730 |
| Beta | 0.22 |
| RSI | 41.71 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cancer Treatments
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cancer Treatments
AstraZeneca (AZN) Sees Leadership Changes at FDA
AstraZeneca (AZN) Sees Leadership Changes at FDA
Top Stock Reports for Costco, Coca-Cola & AstraZeneca
Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift outlooks.
10 Best FTSE 100 Stocks to Buy in 2026 as Analysts Highlight Defence, Pharma and Banking Resilience
Investors are eyeing FTSE 100 stocks like AstraZeneca, HSBC, and Shell for growth and stability in 2026, amid global uncertainty and economic recovery signals.
Sarah Ketterer's Strategic Moves: AstraZeneca PLC Takes Center Stage with 17.66% Portfolio Share
Sarah Ketterer's Strategic Moves: AstraZeneca PLC Takes Center Stage with 17.66% Portfolio Share
AstraZeneca announces results from interim analysis of VOLGA Phase III trial
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI in combination with neoadjuvant enfortumab vedotin demonstrated statisticall...
AstraZeneca announces results interim analysis of Volga Phase III trial
High-level results from a planned interim analysis of the Volga Phase III trial showed perioperative treatment with Imfinzi in combination with neoadjuvant enfortumab vedotin, EV, demonstrated statist...
AstraZeneca Says Imfinzi Combination Improved Survival In Phase III Bladder Cancer Trial
LONDON (dpa-AFX) - AstraZeneca plc (AZN) on Thursday said an interim analysis of the Phase III VOLGA trial showed that perioperative treatment with Imfinzi combined with enfortumab vedotin (EV) si...
AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial
AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bla...
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with A...
AstraZeneca (AZN) Reflects on Changes in FDA Leadership
AstraZeneca (AZN) Reflects on Changes in FDA Leadership
AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Results
AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Results
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory ...
AstraZeneca says CALYPSO Phase III trial met composite primary endpoint
AstraZeneca (AZN) said positive results from the CALYPSO Phase III trial showed that eneboparatide, an investigational parathyroid hormone 1 receptor agonist, met its composite primary endpoint, demon...
AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Quest for Evidence
AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Quest for Evidence
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
How AstraZeneca Plans to Hit $80 Billion in Revenue and Expand in the U.S.
IRW-News: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2 …
IRW-PRESS: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2026 Planung im Tempo des Wandels
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
CDT Equity (CDT) announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca (AZN), has progressed into the patent cooperation treaty phase. A total of 18...
Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions
Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions
What does AstraZeneca's £300m investment mean for Cambridge?
Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.
AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)
AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for AstraZeneca Plc (NASDAQ:AZN), endorsing its prostate cancer regimen while declinin...
AstraZeneca stock falls after FDA panel votes against new cancer drug
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. Astr...
ODAC recommends AstraZeneca Truqap for hormone-sensitive prostate cancer
The FDA Oncologic Drugs Advisory Committee, or ODAC, has recognized a favorable benefit risk profile for AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen deprivation therapy, or...